ArticleScientific reports2024
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Quantitative PSMA PET Biomarkers for Predicting Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Pooled it
- Evaluation of the safety and efficacy ofEuropean radiology experimental · 2026Trial
- Real-world outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- Modernizing disease assessment in prostate cancer trials: the Prostate Cancer Working Group 4 framework.The oncologist · 2026Article
- Tumor heterogeneity in metastatic prostate cancer: Limitations on the efficacy of prostate-specific membrane antigen radioligand therapy.Asian journal of urology · 2026Article
- Novel therapeutic strategies for metastatic castration‑resistant prostate cancer: Beyond androgen receptor pathway inhibition (Review).International journal of oncology · 2026Review
- Lesion-level dual-tracer PET biomarkers predict prognosis in multiple myeloma treated with CXCR4-directed radiopharmaceutical therapy.European journal of nuclear medicine and molecular imaging · 2026Article
- Quantitative characterization ofMolecular imaging and radionuclide therapy · 2026Article
- The role of multimodality imaging in selection, response assessment, and follow-up of patients receivingInsights into imaging · 2026Article
- FDG/PSMA discordance in [Frontiers in oncology · 2026Review
- Enhanced vascular inflammation in patients with advanced prostate cancer receiving hormone therapy.European journal of nuclear medicine and molecular imaging · 2025Article
- Study of predictive factors for response toFrontiers in medicine · 2025Article
- Triple Tracer PET in Advanced Prostate Cancer: Chasing Phenotypic Plasticity.Molecular diagnosis & therapy · 2025Article
- Analysis of Molecular Imaging Biomarkers Derived from [Cancers · 2024Article
- Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candidates for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) frequently have "mismatch" lesions with pronounced 18-fluorodeoxyglucose ([
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.